discovery toxicology studies
Leading the waltz between therapeutic levels and toxic side effects.
Discovery Tox
Discovery Tox is one of the most important tools to assess the potential toxicity profiles of compounds of interest during the discovery stage. When many pharmaceutical companies are adopting the strategy of “kill early, fail cheaply”, discovery tox results become critically important deciding factors when selecting compound for IND.
At PharmaLegacy, we have been providing discovery tox services to clients to speed up their drug discovery process with drug modalities ranging from small molecule, peptide, mAb, and ADC, to gene therapy.
MODELS / SERVICES
Rodent: Mouse, Rat
Dog: Beagle Dog
Monkey: Cynomolgus Monkey
Rabbit: New Zealand Rabbit
Single Dose
Repeat Dose
Intravenous (Bolus and Infusion)
Oral (Solution, Suspension, Tablet or Capsule)
Subcutaneous
Intramuscular
Intraperitoneal
Transdermal
Cage-side Observation and Detailed Clinical Observation
Food / Water Consumption
Body Weight
Clinical Pathology
Macroscopic Observation
Histopathology
Toxicokinetics
Extensively validated preclinical models:
- FDA Part 11 compliant
- 380,000 square feet of facility space
- Capacity to run 200+ concurrent animal studies
- 1,000+ validated animal models available immediately; start your study in under two weeks!
DMPK studies demand flexibility. Can yours meet their goals?
When it comes to DMPK, flexibility is paramount. The right assay and instrumentation are all critical to ensuring you can meet your study goals and obtain meaningful, clinically relevant data.
Download our DMPK brochure and see how PharmaLegacy is equipped to ensure you get the answers you need, no matter how challenging the study.
We’re ready when you are.
Tell us your pharmacology challenges.
